content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on February 22, 2023</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333-</B>&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>NeuroOne
  Medical Technologies Corporation</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.5pt 0.75pt; text-align: center; width: 49%"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
      <TD STYLE="padding: 0.25pt 0.5pt 1.75pt; width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.5pt 0.75pt; text-align: center; width: 49%"><FONT STYLE="font-size: 10pt"><B>27-0863354</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt 0.5pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of<BR>
  </P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.5pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer<BR>
  </P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number.)</P></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.5pt 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>7599 Anagram Dr., <BR>
  Eden Prairie, MN </B></FONT></TD>
      <TD STYLE="padding: 0.25pt 0.5pt 1.75pt">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.5pt 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>55344</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt 0.5pt; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices) </FONT></TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.5pt; text-align: center"><FONT STYLE="font-size: 10pt">(Zip code)</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.5pt 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>NeuroOne Medical Technologies Corporation 2017 Equity Incentive Plan</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt 0.5pt; text-align: center"><FONT STYLE="font-size: 10pt">(Full title of the plan)</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt 0.5pt; text-align: center">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt 0.5pt">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>David Rosa</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>President and Chief Executive Officer</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>7599 Anagram Dr.,<BR>
      Eden Prairie, MN 55344</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>952-426-1383</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-top: black 1.5pt solid">(Name, address,
      and telephone number, including area code, of agent for service)</P></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Copy to:</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Phillip D. Torrence, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Emily Johns, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Honigman LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>650 Trade Centre Way, Suite 200</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Kalamazoo, Michigan 49002-0402</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(269) 337-7700</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo;
  and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Large accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></TD>
      <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Non-accelerated filer <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></FONT></TD>
      <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Smaller reporting company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Emerging growth company <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement on Form S-8 is being
  filed by NeuroOne Medical Technologies Corporation, a Delaware corporation (the <B><I>&ldquo;Company,&rdquo; </I></B>the <B><I>&ldquo;Registrant</I></B>,<B><I>&rdquo;
  &ldquo;we</I></B>,<B><I>&rdquo; &ldquo;us</I></B>,<B><I>&rdquo; or &ldquo;our&rdquo;</I></B>), relating to 129,479 shares of its common
  stock, par value $0.001 per share (the <B><I>&ldquo;Common Stock&rdquo;</I></B>), issuable pursuant to the 2017 Equity Incentive Plan
  (the &ldquo;<B><I>2017 Equity Incentive Plan</I></B>&rdquo;). The Common Stock being registered hereunder is in addition to the (i) 1,300,000
  shares of Common Stock registered on the Registrant&rsquo;s Form S-8 previously filed with the Securities and Exchange Commission (the
  &ldquo;<B><I>Commission</I></B>&rdquo;) on <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390018005312/fs82018_neuroonemedical.htm">May 1, 2018</A> (Commission File No. 333-224572), (ii) 1,079,835 shares of Common Stock registered
  on the Registrant&rsquo;s Form S-8 previously filed with the Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021061596/ea149373-s8_neuroonemedical.htm">November 23, 2021</A> (Commission File No. 333-261302), and (iii)
  1,616,873 shares of Common Stock registered on the Registrant&rsquo;s Form S-8 previously filed with the Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390022004228/ea154559-s8_neuroonemedical.htm">January 28, 2022</A>
  (Commission File No. 333-262397) (collectively, the &ldquo;<B><I>Prior Registration Statements</I></B>&rdquo;).</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This Registration Statement
  relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with
  General Instruction E to Form S-8 regarding the registration of additional securities. Pursuant to such instruction, the contents of the
  Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3. Incorporation of Documents by Reference.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Pursuant to General Instruction
  E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The following documents filed
  with the Commission by the Registrant are hereby incorporated by reference in this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390022081897/f10k2022_neuroone.htm">Form 10-K</A> for the year ended September 30, 2022 filed with the Commission on December 22, 2022;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our Current Reports on Form 8-K filed with the Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390022065984/ea167480-8k_neuroone.htm">October 25, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390022080515/ea170343-8k_neuroone.htm">December 16, 2022</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390023002798/ea171657-8k_neuroone.htm">January 13, 2023</A>; </FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="text-align: justify">&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our definitive proxy statement for the annual meeting of stockholders held on March 16, 2023, filed with the Commission on <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390023005481/def14a0123_neuroonemedtech.htm">January 27, 2023</A>; and</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the description of our Common Stock in our registration statement on Form 8-A filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021028934/ea141508-8a12b_neuroone.htm">May 25, 2021</A> and as amended by any subsequent amendment or report filed for the purpose of updating such description.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">In addition, all documents
  the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the
  <B><I>&ldquo;Exchange Act&rdquo;</I></B>), after the filing of this Registration Statement and prior to the filing of a post-effective
  amendment which indicates that all securities offered hereby have been sold or which deregisters all securities covered hereby then remaining
  unsold are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents. Notwithstanding
  anything herein, the Registrant is not incorporating by reference any information furnished under Item 2.02 or Item 7.01 of any Current
  Report on Form 8-K, unless, and to the extent, specified in any such Current Report on Form 8-K.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Any statement herein or contained
  in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes
  of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or
  is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded
  shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt"></P>
  
  <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8. Exhibits.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following exhibits are filed as part of this
  registration statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
    <TR>
      <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; padding: 0.25pt 0.5pt 0.75pt; width: 9%">
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit</B></P>
      <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number</B></P></TD>
      <TD STYLE="padding: 0.25pt 0.5pt; width: 1%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; padding: 0.25pt 0.5pt 0.75pt; text-align: center; width: 90%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417034948/v470040_ex3-4.htm">Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.4 on the Registrant&rsquo;s Current Report on Form 8-K filed on June, 29, 2017)</A></FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021018989/ea138690ex3-1_neuroone.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on March 31, 2021)</A></FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417034948/v470040_ex3-5.htm">Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.5 on the Registrant&rsquo;s Current Report on Form 8-K filed on June 29, 2017)</A></FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">4.4&dagger;</FONT></TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417021319/v464727_def14c.htm">2017 Equity Incentive Plan (incorporated by reference to Appendix G to Schedule 14C filed on April 20, 2017).</A></FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea173417ex5-1_neuroone.htm">Opinion of Honigman LLP</A></FONT></TD></TR>
    <TR STYLE="background-color: Transparent">
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt 1pt; text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
      <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea173417ex23-1_neuroone.htm">Consent of Baker Tilly US, LLP</A></FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">23.2</FONT></TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt; text-align: justify"><A HREF="ea173417ex5-1_neuroone.htm"><FONT STYLE="font-size: 10pt">Consent of Honigman LLP (included in its opinion filed as Exhibit 5.1 to this Registration Statement)</FONT></A></TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">24.1</FONT></TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_001">Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement)</A></FONT></TD></TR>
    <TR STYLE="background-color: Transparent">
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt 1pt; text-align: justify">&nbsp;</TD></TR>
    <TR STYLE="background-color: #CCEEFF">
      <TD STYLE="vertical-align: top; padding: 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">107</FONT></TD>
      <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt 0.5pt 1pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="ea173417ex-fee_neuroone.htm">Filing Fee Table</A></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">&dagger;</FONT></TD>
      <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Indicates management compensatory plan, contract or arrangement.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 4; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Act, the registrant
  certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this
  Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Eden Prairie, State of
  Minnesota, on February 22, 2023.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="padding: 0.25pt"><FONT STYLE="font-size: 10pt"><B>NeuroOne Medical Technologies Corporation</B></FONT></TD></TR>
    <TR>
      <TD STYLE="width: 60%; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="width: 4%; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="width: 36%; padding: 0.25pt">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt"><FONT STYLE="font-size: 10pt">/s/ David Rosa</FONT></TD></TR>
    <TR>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-size: 10pt">David Rosa</FONT></TD></TR>
    <TR>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-size: 10pt"><I>President and Chief Executive Officer</I></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>POWER OF ATTORNEY </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each person whose signature appears below constitutes
  and appoints David Rosa and Ronald McClurg, or either of them, as his or her true and lawful attorneys-in-fact and agents, with the full
  power of substitution and resubstitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any
  and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto
  and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents,
  and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection
  therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said
  attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by
  virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
  Act, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 40%"><FONT STYLE="font-size: 10pt"><B>Signature </B></FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 37%"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
      <TD STYLE="width: 1%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 21%"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ David Rosa</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center">February 22, 2023</TD></TR>
    <TR>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">David Rosa</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">(Principal Executive Officer) and a Director</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Ronald McClurg</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Chief Financial Officer (Principal Financial </FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">February 22, 2023</FONT></TD></TR>
    <TR>
      <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Ronald McClurg</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Officer and Principal Accounting Officer)</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul Buckman</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">February 22, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Paul Buckman</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Jeffrey Mathiesen</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">February 22, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Jeffrey Mathiesen</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Edward Andrle</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">February 22, 2023</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Edward Andrle</FONT></TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD>
      <TD>&nbsp;</TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">II-3</P>
  <P STYLE="margin: 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="margin: 0">&nbsp;</P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea173417-s8_neuroonemedical.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 39339}]
metadata_filer: {"company-data": {"conformed-name": "NEUROONE MEDICAL TECHNOLOGIES Corp", "cik": "0001500198", "assigned-sic": "3841", "irs-number": "270863354", "state-of-incorporation": "DE", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-269910", "film-number": "23653329"}, "business-address": {"street1": "7599 ANAGRAM DR", "city": "EDEN PRAIRIE", "state": "MN", "zip": "55344", "phone": "(952) 426-1383"}, "mail-address": {"street1": "7599 ANAGRAM DR", "city": "EDEN PRAIRIE", "state": "MN", "zip": "55344"}, "former-company": {"former-conformed-name": "Original Source Entertainment, Inc.", "date-changed": "20100830"}}
text: As filed with the Securities and Exchange Commission
  on February 22, 2023
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER
  THE SECURITIES ACT OF 1933
  NeuroOne
  Medical Technologies Corporation
  (Exact name of registrant as specified in its charter)
  Delaware
  27-0863354
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer
  Identification Number.)
  7599 Anagram Dr.,
  Eden Prairie, MN
  55344
  (Address of principal executive offices)
  (Zip code)
  NeuroOne Medical Technologies Corporation 2017 Equity Incentive Plan
  (Full title of the plan)
  David Rosa
  President and Chief Executive Officer
  NeuroOne Medical Technologies Corporation
  7599 Anagram Dr.,
  Eden Prairie, MN 55344
  952-426-1383
  (Name, address,
      and telephone number, including area code, of agent for service)
  Copy to:
  Phillip D. Torrence, Esq.
  Emily Johns, Esq.
  Honigman LLP
  650 Trade Centre Way, Suite 200
  Kalamazoo, Michigan 49002-0402
  (269) 337-7700
  Indicate by check mark whether the registrant
  is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
  See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company,"
  and "emerging growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Non-accelerated filer
  ☒
  Smaller reporting company
  ☒
  Emerging growth company
  ☐
  If an emerging growth company, indicate by check
  mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
  standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
  ☐
  EXPLANATORY NOTE
  This Registration Statement on Form S-8 is being
  filed by NeuroOne Medical Technologies Corporation, a Delaware corporation (the
  "Company,"
  the
  "Registrant
  ,
  "
  "we
  ,
  " "us
  ,
  " or "our"
  ), relating to 129,479 shares of its common
  stock, par value $0.001 per share (the
  "Common Stock"
  ), issuable pursuant to the 2017 Equity Incentive Plan
  (the "
  2017 Equity Incentive Plan
  "). The Common Stock being registered hereunder is in addition to the (i) 1,300,000
  shares of Common Stock registered on the Registrant's Form S-8 previously filed with the Securities and Exchange Commission (the
  "
  Commission
  ") on
  May 1, 2018
  (Commission File No. 333-224572), (ii) 1,079,835 shares of Common Stock registered
  on the Registrant's Form S-8 previously filed with the Commission on
  November 23, 2021
  (Commission File No. 333-261302), and (iii)
  1,616,873 shares of Common Stock registered on the Registrant's Form S-8 previously filed with the Commission on
  January 28, 2022
  (Commission File No. 333-262397) (collectively, the "
  Prior Registration Statements
  ").
  This Registration Statement
  relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with
  General Instruction E to Form S-8 regarding the registration of additional securities. Pursuant to such instruction, the contents of the
  Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3. Incorporation of Documents by Reference.
  Pursuant to General Instruction
  E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference.
  The following documents filed
  with the Commission by the Registrant are hereby incorporated by reference in this Registration Statement:
  (a)
  our Annual Report on
  Form 10-K
  for the year ended September 30, 2022 filed with the Commission on December 22, 2022;
  (b)
  our Current Reports on Form 8-K filed with the Commission on
  October 25, 2022
  ,
  December 16, 2022
  , and
  January 13, 2023
  ;
  (c)
  our definitive proxy statement for the annual meeting of stockholders held on March 16, 2023, filed with the Commission on
  January 27, 2023
  ; and
  (d)
  the description of our Common Stock in our registration statement on Form 8-A filed with the SEC on
  May 25, 2021
  and as amended by any subsequent amendment or report filed for the purpose of updating such description.
  In addition, all documents
  the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the
  "Exchange Act"
  ), after the filing of this Registration Statement and prior to the filing of a post-effective
  amendment which indicates that all securities offered hereby have been sold or which deregisters all securities covered hereby then remaining
  unsold are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents. Notwithstanding
  anything herein, the Registrant is not incorporating by reference any information furnished under Item 2.02 or Item 7.01 of any Current
  Report on Form 8-K, unless, and to the extent, specified in any such Current Report on Form 8-K.
  Any statement herein or contained
  in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes
  of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or
  is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded
  shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.
  II-
  1
  Item 8. Exhibits.
  EXHIBIT INDEX
  The following exhibits are filed as part of this
  registration statement.
  INDEX TO EXHIBITS
  Exhibit
  Number
  Description
  4.1
  Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.4 on the Registrant's Current Report on Form 8-K filed on June, 29, 2017)
  4.2
  Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant's Current Report on Form 8-K filed on March 31, 2021)
  4.3
  Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.5 on the Registrant's Current Report on Form 8-K filed on June 29, 2017)
  4.4†
  2017 Equity Incentive Plan (incorporated by reference to Appendix G to Schedule 14C filed on April 20, 2017).
  5.1
  Opinion of Honigman LLP
  23.1
  Consent of Baker Tilly US, LLP
  23.2
  Consent of Honigman LLP (included in its opinion filed as Exhibit 5.1 to this Registration Statement)
  24.1
  Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement)
  107
  Filing Fee Table
  †
  Indicates management compensatory plan, contract or arrangement.
  II-
  2
  SIGNATURES
  Pursuant to the requirements of the Securities Act, the registrant
  certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this
  Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Eden Prairie, State of
  Minnesota, on February 22, 2023.
  NeuroOne Medical Technologies Corporation
  By:
  /s/ David Rosa
  David Rosa
  President and Chief Executive Officer
  POWER OF ATTORNEY
  Each person whose signature appears below constitutes
  and appoints David Rosa and Ronald McClurg, or either of them, as his or her true and lawful attorneys-in-fact and agents, with the full
  power of substitution and resubstitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any
  and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto
  and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents,
  and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection
  therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said
  attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by
  virtue hereof.
  Pursuant to the requirements of the Securities
  Act, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.
  Signature
  Title
  Date
  /s/ David Rosa
  President and Chief Executive Officer
  February 22, 2023
  David Rosa
  (Principal Executive Officer) and a Director
  /s/ Ronald McClurg
  Chief Financial Officer (Principal Financial
  February 22, 2023
  Ronald McClurg
  Officer and Principal Accounting Officer)
  /s/ Paul Buckman
  Director
  February 22, 2023
  Paul Buckman
  /s/ Jeffrey Mathiesen
  Director
  February 22, 2023
  Jeffrey Mathiesen
  /s/ Edward Andrle
  Director
  February 22, 2023
  Edward Andrle
  II-3